The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I expansion study of the first-in-class monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL).
 
Sarah E. R. Halford
No Relationships to Disclose
 
Harriet Walter
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Janssen
 
Pamela McKay
Consulting or Advisory Role - Beigene; Celgene; Gilead Sciences; Roche; TAKEDA
 
William Townsend
Honoraria - Roche
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - Roche
 
Kim Linton
Honoraria - Aptitude Health; Hartley Taylor Medical; Janssen-Cilag; Roche/Genentech
Consulting or Advisory Role - CTI; Janssen Oncology; Janssen Oncology; Takeda; Takeda; Takeda
Speakers' Bureau - BeiGene; Celgene; Karyopharm Therapeutics; Roche/Genentech; Takeda
Research Funding - Millennium (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Celgene; Janssen Oncology; Janssen Oncology; Takeda
 
Kathrin Heinzmann
No Relationships to Disclose
 
Ilaria Dragoni
No Relationships to Disclose
 
Laura Brotherton
No Relationships to Disclose
 
Gareth Veal
Consulting or Advisory Role - Novartis (Inst); Sanofi (Inst)
 
Alexandros Siskos
No Relationships to Disclose
 
Hector C Keun
No Relationships to Disclose
 
Chris Bacon
No Relationships to Disclose
 
George Petrides
No Relationships to Disclose
 
Steve Wedge
Stock and Other Ownership Interests - AstraZeneca
Research Funding - Astex Pharmaceuticals
 
Martin J.S. Dyer
Honoraria - Abbvie; Roche Pharma AG; Sandoz; TEVA
Speakers' Bureau - Kite/Gilead; Kite/Gilead; Teva
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bioinvent (Inst); Gilead Sciences (Inst); Roche (Inst)
 
Elizabeth Ruth Plummer
Honoraria - Amgen (I); AstraZeneca/MedImmune; Bristol-Myers Squibb; Novartis Pharmaceuticals UK Ltd.; Pfizer (I); Tesaro
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Biosceptre; Clovis Oncology; CV6 Therapeutics; Cybrexa Therapeutics; Ellipses Pharma; Karus Therapeutics; Novartis; Octimet; Pierre Fabre; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology